[Nivolumab, a new hope in non-small cell lung cancer].
Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of twoyears in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and sustainable survival in lung cancer patients. The approval of Nivolumab in this setting will lead to drastic changes in clinical practice. For optimal patient care, it will be essential to integrate the benefits and risks of such treatment. This review aims at discussing the role of nivolumab in lung cancer, in consideration of updated clinical data for safety and efficacy.